John DiPersio, MD, PhD, Washington University School of Medicine, St. Louis, MO, talks on the potential of a streptavidin (SAv)-biotin platform that allows testing different toxins together to determine the optimal toxic payload for antibody-based stem cell transplantation (SCT) conditioning. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.